Classed as a CD33-related Siglec, Siglec-7 preferentially binds to glycoconjugates containing alpha-2,3- or alpha-2,6-linked sialic acid, and acts as a novel inhibitory receptor for NK cells, mediating the inhibition of NK cell cytotoxicity, and implicated in the regulation of NK cell and T cell activation, and hematopoiesis.
Pathway
Allograft rejection; Autoimmune thyroid disease; Cell adhesion molecules (CAMs); Graft-versus-host disease; Inflammatory Response Pathway; Intestinal immune network for IgA production; Measles; Rheumatoid arthritis; Systemic lupus erythematosus; T cell receptor signaling pathway; Type I diabetes mellitus; Viral myocarditis
Citations
Publication ()
Have you cited DCABY-657 in a publication? Let us know and earn a reward for your research.
My Review for Anti-SIGLEC7 monoclonal antibody, clone T8.8
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
